The clinical performance is complex and often involves multiple systems. Early identification and standardized clinical care are essential for improving prognosis. The diagnosis of the disease requires a combination of clinical performance, imaging inspection, laboratory testing and pathological activation.
The platform can assist in matching authoritative experts and teams at home and abroad to provide accurate diagnosis and treatment programs. In recent years, with the development of therapeutic, immune-regulatory therapy and precision medicine, many autoimmune and rheumatic immune diseases that were previously difficult to treat have been significantly improved. Treatment needs to be closely monitored for efficacy and adverse reactions, adapted to timely regimens according to changes in conditions.
Multidisciplinary collaboration (MDT) is particularly important for the comprehensive management of lupus type II. The platform serves a team of internationally authoritative experts in the field of autoimmune and rheumatic immunity in China, providing the following services to patients: 2. Visiting China: arranging face-to-face treatment with authoritative experts, developing individualized treatment plans; 3.
Full-service: providing one-stop services such as medical translation, medical care, accommodation arrangements; 4. Long-term follow-up: establishing a chronic disease management archive, continuous monitoring of disease changes and treatment effects.